Literature DB >> 16944143

Pathology of primary malignant bone and cartilage tumours.

L B Rozeman1, A M Cleton-Jansen, P C W Hogendoorn.   

Abstract

Bone- and cartilage-forming tumours (osteosarcomas and chondrosarcomas) are rare malignant neoplasms. These tumours are clinically aggressive and often need extensive local and/or systemic treatment. Whereas no other treatment but surgery is currently available for chondrosarcomas, osteosarcomas show an approximately 50-80% response rate to adjuvant chemotherapy. Surgical removal of these tumours is currently mostly performed with limb salvage, but amputation may be required in some cases. In addition, the tumours have a risk of local recurrences adversely affecting the prognosis compared to the primary tumour. In this report we will mainly focus on two of the most prevalent malignant bone tumours, conventional osteosarcoma and conventional chondrosarcoma, and use these to illustrate the problems with the diagnosis of bone sarcomas in general.

Entities:  

Mesh:

Year:  2006        PMID: 16944143      PMCID: PMC3172744          DOI: 10.1007/s00264-006-0212-x

Source DB:  PubMed          Journal:  Int Orthop        ISSN: 0341-2695            Impact factor:   3.075


  30 in total

1.  [Assessment of the grading of cartilaginous tumors of the long tubular bones from the radiologic and pathologic viewpoint].

Authors:  M Dietlein; W Féaux de Lacroix; K F Neufang; W Steinbrich; J Schmidt
Journal:  Rontgenblatter       Date:  1990-05

2.  Prognostic factors in chondrosarcoma of bone: a clinicopathologic analysis with emphasis on histologic grading.

Authors:  H L Evans; A G Ayala; M M Romsdahl
Journal:  Cancer       Date:  1977-08       Impact factor: 6.860

3.  Usefulness of radiography in differentiating enchondroma from central grade 1 chondrosarcoma.

Authors:  M J Geirnaerdt; J Hermans; J L Bloem; H M Kroon; T L Pope; A H Taminiau; P C Hogendoorn
Journal:  AJR Am J Roentgenol       Date:  1997-10       Impact factor: 3.959

Review 4.  Etiology of osteosarcoma.

Authors:  Bruno Fuchs; Douglas J Pritchard
Journal:  Clin Orthop Relat Res       Date:  2002-04       Impact factor: 4.176

5.  A new histologic approach to the differentiation of enchondroma and chondrosarcoma of the bones. A clinicopathologic analysis of 51 cases.

Authors:  J M Mirra; R Gold; J Downs; J J Eckardt
Journal:  Clin Orthop Relat Res       Date:  1985-12       Impact factor: 4.176

6.  Imaging of intramedullary tumour spread in osteosarcoma. A comparison of techniques.

Authors:  S J O'Flanagan; J P Stack; H M McGee; P Dervan; B Hurson
Journal:  J Bone Joint Surg Br       Date:  1991-11

Review 7.  Biology and therapeutic advances for pediatric osteosarcoma.

Authors:  Neyssa Marina; Mark Gebhardt; Lisa Teot; Richard Gorlick
Journal:  Oncologist       Date:  2004

8.  Cartilaginous tumors: correlation of gadolinium-enhanced MR imaging and histopathologic findings.

Authors:  M J Geirnaerdt; J L Bloem; F Eulderink; P C Hogendoorn; A H Taminiau
Journal:  Radiology       Date:  1993-03       Impact factor: 11.105

9.  Diagnosis of borderline cartilage lesions of bone.

Authors:  A L Schiller
Journal:  Semin Diagn Pathol       Date:  1985-02       Impact factor: 3.464

10.  The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis.

Authors:  Chand Khanna; Xiaolin Wan; Seuli Bose; Ryan Cassaday; Osarenoma Olomu; Arnulfo Mendoza; Choh Yeung; Richard Gorlick; Stephen M Hewitt; Lee J Helman
Journal:  Nat Med       Date:  2004-01-04       Impact factor: 53.440

View more
  28 in total

1.  Cytotoxic effect of clodronate and zoledronate on the chondrosarcoma cell lines HTB-94 and CAL-78.

Authors:  Arne Streitbuerger; Marcel Henrichs; Helmut Ahrens; Claudia Lanvers-Kaminzky; Francois Gouin; Georg Gosheger; Jendrik Hardes
Journal:  Int Orthop       Date:  2010-10-02       Impact factor: 3.075

Review 2.  Review of microRNA in osteosarcoma and chondrosarcoma.

Authors:  Le Chang; Swati Shrestha; Greg LaChaud; Michelle A Scott; Aaron W James
Journal:  Med Oncol       Date:  2015-04-26       Impact factor: 3.064

3.  Chondrosarcoma of the para-acetabulum: correlation of imaging features with histopathological grade.

Authors:  Yanqing Kang; Weiwei Yuan; Xiaoyi Ding; Guangbin Wang
Journal:  Radiol Med       Date:  2016-08-23       Impact factor: 3.469

4.  Downregulation of miR-185 and upregulation of miR-218 expression may be potential diagnostic and prognostic biomarkers of human chondrosarcoma.

Authors:  Peyman Karimi Goudarzi; Afshin Taheriazam; Saeid Asghari; Mohammad Jamshidi; Mohammadreza Shakeri; Emad Yahaghi; Alireza Mirghasemi
Journal:  Tumour Biol       Date:  2015-09-18

5.  Primary osteosarcoma of the clavicle and the perils of bone biopsy.

Authors:  William J Cundy; Christopher Carter; Deepak Dhatrak; Mark Clayer
Journal:  BMJ Case Rep       Date:  2015-04-24

6.  The impact of pathological fractures on therapy outcome in patients with primary malignant bone tumours.

Authors:  Babak Moradi; Anita Zahlten-Hinguranage; Burkhard Lehner; Felix Zeifang
Journal:  Int Orthop       Date:  2009-12-13       Impact factor: 3.075

7.  Loss of RUNX3 expression may contribute to poor prognosis in patients with chondrosarcoma.

Authors:  Zhe Jin; Ya-Xin Han; Xiao-Rui Han
Journal:  J Mol Histol       Date:  2013-05-12       Impact factor: 2.611

Review 8.  Treatment strategies for central low-grade chondrosarcoma of long bones: a systematic review of the literature and meta-analysis.

Authors:  S S Shemesh; J D Acevedo-Nieves; J Pretell-Mazzini
Journal:  Musculoskelet Surg       Date:  2017-10-06

9.  Differentiating high-grade from low-grade chondrosarcoma with MR imaging.

Authors:  Hye Jin Yoo; Sung Hwan Hong; Ja-Young Choi; Kyung Chul Moon; Han-Soo Kim; Jung-Ah Choi; Heung Sik Kang
Journal:  Eur Radiol       Date:  2009-12       Impact factor: 5.315

10.  Analysis of microRNAs expressions in chondrosarcoma.

Authors:  Teruhito Yoshitaka; Akira Kawai; Shigeru Miyaki; Kunihiko Numoto; Kazutaka Kikuta; Toshifumi Ozaki; Martin Lotz; Hiroshi Asahara
Journal:  J Orthop Res       Date:  2013-08-12       Impact factor: 3.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.